08.01.2021 16:31:26

Stock Alert: Chimerix Surges 60% On Acquisition Of Oncoceutics

(RTTNews) - Shares of Chimerix, Inc. (CMRX) surged over 60% on Friday morning after the biopharmaceutical company announced acquisition of Oncoceutics to expand pipeline with late-stage oncology program.

CMRX is currently trading at $8.03, up $3.05 or 61.16%, on the Nasdaq.

Chimerix announced that the company has acquired Oncoceutics, a privately held, clinical-stage biotechnology company developing imipridones, a novel class of compounds.

Oncoceutics' lead product candidate, ONC201, has been shown in clinical testing to selectively induce cell death in multiple cancer types. ONC201 is currently in a registrational clinical trial for recurrent H3 K27M-mutant glioma and a confirmatory response rate assessment is expected in 2021.

Chimerix will pay Oncoceutics shareholders $78 million, of which $39 million is payable in Chimerix stock and $39 million in cash. The payment of $39 million in cash is split $25 million at closing and $14 million on the first anniversary of closing.

Analysen zu Chimerix Incmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Chimerix Inc 3,44 2,84% Chimerix Inc